-
Trial Begins Testing RNA Hepatitis-B Treatment
A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease.
-
Hydrogel Biomaterials Company Raises $3M in Early Funds
A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round.
-
Start-Up to Manufacture, Supply Practical Radiation Drugs
A new company formed by a technology venture investor and the Mayo Clinic aims to produce and supply more readily available radiation drug therapies.
-
Gene Therapy Stimulates Missing Enzymes in Rare Disease
Results from a clinical trial show an experimental gene therapy for Krabbe disease is safe and produces enzymes missing in children with the rare disease.
-
Drug Licensed for Precision Autism Spectrum Therapies
A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress.
-
Infographic – Sharp Drop in Q3 Venture Funds
Total venture investing worldwide dropped to $81 billion in July to September 2022, a decline of $40 billion or one-third compared to the second quarter of the year.
-
RNA Cancer Immunotherapy Shown Feasible in Preclinical Test
Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors.
-
Nasal Spray Vaccines Get CEPI, NIH Funding
A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea.
-
Yom Kippur 5783
Regular posting will resume tomorrow, Thursday, 6 Oct.
-
Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test
A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria.